Thursday 16 October, 2025
Objectives: Vinpocetine holds a dual status as both a prescription drug in the EU and an ingredient in dietary supplements. Its…
Read moreAbstracts
From physiology to disease: A quantitative framework for system-disease-drug interaction in cortisol replacement therapy
Thursday 16 October, 2025
Objectives: Congenital adrenal hyperplasia (CAH) is characterised by a decreased or absent cortisol production, mainly caused by reduced 21-hydroxylase enzyme activity….
Read moreSemi-mechanistic model-based analysis of plasma and target-site cefazolin pharmacokinetics and protein binding in obese and nonobese patients
Thursday 16 October, 2025
Objectives: Cefazolin (CEZ) is frequently used for the treatment of skin and soft tissue infections (SSTI), e.g. after surgery. Obesity…
Read moreUnderstanding the physiology of the hypothalamic-pituitary-adrenal axis to optimise cortisol replacement therapy: A quantitative modelling framework
Thursday 16 October, 2025
Objectives: Congenital adrenal hyperplasia (CAH) is a life-threatening condition characterised by a loss of cortisol secretion, mainly caused by a deficiency…
Read moreIndividualized Prediction of Gentamicin Concentration in Neonates: A Multimodal Approach of PBPK Modeling and Machine Learning
Thursday 16 October, 2025
Objectives: The efficacy of drug therapy in neonates critically depends on selecting appropriate dosage regimens. Physiologically based pharmacokinetic (PBPK) modelling…
Read moreIntegrating Python optimization algorithms inside PhysPK® (PK/PD/PBPK) software for improving PK estimation methods.
Thursday 16 October, 2025
Introduction/Objectives: Characterization of the pharmacokinetics (PK) and pharmacodynamics (PD) of a drug product through mathematical modelling approaches of the relationships…
Read moreGround-breaking software for modelling, simulation, optimization, estimation and validation applications in drug development timeline processes.
Thursday 16 October, 2025
Introduction: With the rapidly changing health care and research environments, it has become essential that the drug development process achieve…
Read moreDose Adaptations for Drug-Gene and Drug-Drug Interactions involving Clopidogrel – A Physiologically based Pharmacokinetic (PBPK) Modeling Approach
Thursday 16 October, 2025
Introduction: The antiplatelet agent clopidogrel is widely used for the prevention of atherothrombotic events [1]. Clopidogrel’s active metabolite (Clo-AM) is…
Read morePhysiologically Based Pharmacokinetic Modeling of Imatinib and Its Main Metabolite for Drug–Drug Interaction Predictions
Thursday 16 October, 2025
Introduction: Since its approval in 2001, the tyrosine kinase inhibitor imatinib has revolutionized the development of targeted cancer therapy and,…
Read moreUnraveling the CYP2D6 Drug-Drug-Gene Interaction Network: A Comprehensive PBPK Analysis of Key Substrates and Inhibitors
Thursday 16 October, 2025
Introduction: Drug-drug interactions (DDIs) and drug-gene interactions (DGIs) are key drivers of adverse drug reactions [1], posing substantial challenges in…
Read more